Article Text

Download PDFPDF

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit
  1. P Sidiropoulos1,2,
  2. G Bertsias1,
  3. H D Kritikos1,
  4. H Kouroumali1,
  5. K Voudouris2,
  6. D T Boumpas1
  1. 1University Hospital, Medical School, University of Crete, Heraklion, Greece
  2. 2First General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece
  1. Correspondence to:
    Professor D T Boumpas
    Department of Internal Medicine, Division of Rheumatology, Clinical Immunology and Allergy, University of Crete, Medical School, Voutes 71500, Heraklion, Greece; boumpasdmed.uoc.gr

Abstract

Background: Randomised controlled trials have shown that treatment with anti-tumour necrosis factor (anti-TNF) agents is effective in refractory rheumatoid arthritis (RA).

Objective: To determine the effectiveness of anti-TNF in a general unselected group of patients with refractory RA.

Methods: 68 patients with active RA despite treatment with disease modifying antirheumatic drugs were studied during 12 infliximab infusions. Infliximab (3 mg/kg/infusion) was given every 8 or 6 weeks. Clinical efficacy was assessed by the Disease Activity Score (DAS) index (44 joints). Dose adjustments were based on residual disease activity (DAS score >2.4). The primary end points were the percentage of patients achieving good or moderate response by the EULAR response criteria and the proportion of patients requiring dose adjustment.

Results: 20 (29%) patients discontinued treatment owing to side effects, early inefficacy, or other considerations. Among the patients who continued treatment, 27 (56%) and 32 (67%) were responders on the 6th and 12th infliximab infusion, respectively. In the same patients, disease activity gradually improved without modifications in the initial dosing in 10 (21%), whereas in 38 (79%) the dose of infliximab and/or methotrexate was increased. Intensification of treatment led to a significant decrease in the mean DAS score in this group (from 5.27 just before dose modification to 4.54 before the 12th infusion, p<0.002). The EULAR response category improved in only 10/38 (26%), however.

Conclusions: In this initial observational study of patients with RA treated with recommended doses of infliximab, adjustments in treatment were common but not always sufficient to maintain adequate disease control. Longitudinal controlled trials are needed to define the optimal dose escalation in patients with suboptimal response.

  • rheumatoid arthritis
  • infliximab
  • Disease Activity Score
  • EULAR response criteria
  • ACR, American College of Rheumatology
  • CRP, C reactive protein
  • DAS, Disease Activity Score
  • DMARD, disease modifying antirheumatic drug
  • ESR, erythrocyte sedimentation rate
  • HAQ, Health Assessment Questionnaire
  • PPD, purified protein derivative
  • RA, rheumatoid arthritis
  • RCT, randomised controlled trial
  • TB, tuberculosis
  • TNFα, tumour necrosis factor α
  • VAS, visual analogue scale
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.